Verve Therapeutics
About Us
Why Cardiovascular Disease
Our Approach
Our Pipeline
Culture & Careers
Investors
Overview
News & Events
Stock Information
Corporate Governance
Financials & Filings
IR Resources
With a superstar cardiologist as its CEO, new CRISPR company targets heart disease
Post navigation
Previous Post
Previous
One of the world’s top experts in coronary heart disease is spearheading a new gene editing upstart out to transform the field
Next Post
Next
One-off injection may drastically reduce heart attack risk
Home
About Us
Why Cardiovascular Disease
Our Approach
Our Pipeline
Culture & Careers
Investors
►
◄ Back
Overview
News & Events
Stock Information
Corporate Governance
Financials & Filings
IR Resources
Contact Us